C4X Discovery And Acellera Collaborate To Shed Light On The Mechanisms Of Action Of Anti-Cancer Drugs
Published on March 30, 2022
This new collaboration between C4X Discovery (“C4XD”) and Acellera aims to elucidate the binding mode of a library of new anti-cancer lead compounds against a specific therapeutic target to develop new, more effective drugs against difficult-to-treat cancers.
Acellera will use its proprietary technology in machine learning and molecular simulations towards computable drug discovery through its PlayMolecule® and ACEMD® software to shed light on the mechanisms of action of these molecules, leveraging expertise in medicinal chemistry and structure and ligand-based drug design. C4XD will combine insights from Acellera’s software with 4D ligand data from C4XD’s Conformetrix platform and utilise its expertise in Drug Discovery to design novel and potent molecules with improved physio-chemical properties.
“We at Acellera are excited to see how joining know-how and technologies in machine learning and simulations with C4XD will advance drug discovery to deliver new and better therapeutics for patients” said CEO, CSO, founder, Dr. Gianni De Fabritiis.
About C4X Discovery
C4X Discovery (“C4XD”) combines scientific expertise with drug discovery technologies. Its work includes target identification and candidate molecule design across multiple disease areas.
The company collaborates with pharmaceutical and life sciences organisations across drug discovery research.
About Acellera
Acellera is a software company founded in 2006. It builds molecular simulation, molecular physics and AI applications for drug discovery. Its products include PlayMolecule AI, QuantumBind Lab and ACEMD Toolkit.
For more information please visit: www.acellera.com
contact: info@acellera.com